Physician profile
Maria E Ramirez
NPI 1952755027
$7,137.98
in general payments reported to CMS, 2019-2025
40 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $756 · 2022: $1,199 · 2023: $1,245 · 2024: $1,863 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,097 · Education: $85.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,097.05 |
| Education | $85.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,084.09 | 2021-2025 | Jakafi, Jakafi, Zynyz |
| Daiichi Sankyo INC. | $943.24 | 2022-2025 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $649.23 | 2021-2025 | |
| Genzyme Corporation | $501.17 | 2021-2025 | |
| Sobi, INC | $495.22 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $361.88 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals Lp | $280.17 | 2022-2025 | Enhertu |
| Amgen INC. | $238.10 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $219.15 | 2022 | |
| Pharmaessentia USA Corporation | $194.24 | 2024-2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $191.91 | 2022-2024 | Vonvendi, Fruzaqla |
| Pfizer INC. | $180.54 | 2021-2024 | |
| Pharmacosmos Therapeutics INC. | $147.99 | 2024-2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $138.53 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $134.41 | 2022-2025 | Pyrukynd |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $133.33 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $114.99 | 2021 | |
| Lilly USA, LLC | $97.91 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Apellis Pharmaceuticals, INC. | $93.98 | 2022-2025 | Empaveli |
| Geron Corporation | $85.27 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $80.11 | 2024 | Sylvant |
| Taiho Oncology, INC. | $76.53 | 2023-2025 | |
| Eisai INC. | $66.02 | 2025 | |
| Blueprint Medicines Corporation | $57.26 | 2025 | Ayvakit |
| Janssen Pharmaceuticals, INC | $55.63 | 2024 | Xarelto |
| Springworks Therapeutics, INC. | $55.09 | 2025 | Ogsiveo |
| Csl Behring | $54.31 | 2023 | Hemgenix, Idelvion |
| Alnylam Pharmaceuticals INC. | $50.76 | 2022-2023 | Givlaari |
| Jazz Pharmaceuticals INC. | $50.34 | 2025 | |
| Stemline Therapeutics INC. | $38.91 | 2024 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $38.73 | 2024 | Onivyde, Somatuline Depot |
| Global Blood Therapeutics, INC. | $36.78 | 2022 | |
| Janssen Scientific Affairs, LLC | $33.33 | 2021 | |
| Dova Pharmaceuticals | $32.79 | 2021 | |
| Astellas Pharma US INC | $24.62 | 2021 | |
| Genmab U.S., INC. | $23.81 | 2025 | Epkinly |
| Kedrion Biopharma, INC. | $22.61 | 2024 | Gammaked, Koate, Kedrab |
| Bard Peripheral Vascular, INC. | $21.69 | 2024 | Denali Vena Cava Filter |
| Novo Nordisk INC | $18.07 | 2021 | |
| Becton, Dickinson and Company | $15.24 | 2024 | Venclose Maven Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.